India's WTO Patent Bill Fails In Parliament

9 April 1995

The Indian government has failed to secure parliamentary approval for its Patents (Amendments) Bill, which is required as part of its obligation under its membership of the World Trade Organization from January 1, 1995 (Marketletter April 3).

The bill was passed by the lower house of parliament during the week ending March 26, when the ordinance which it replaces was due to lapse. However, opposition parties in the upper house, where the government does not have a majority, forced consideration of the legislation to be deferred.

As the bill failed to be passed by parliament within six weeks from the day the current budget session commenced in February, the government is now required to produce a new bill and try to get it passed by both houses separately, or through a joint sitting. A new bill is not expected for at least a month.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight